Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Early publications reported higher rates of coagulopathies in the form of prolonged prothrombin time and elevated D-dimer levels in severe cases of COVID-19 [1]. These findings led to a prospective study by Tang et al. of 183 patients in Wuhan, China that showed derangements in coagulation parameters during COVID-19 were significantly associated with poorer prognosis [2]. Furthermore, patients with COVID-19 coagulopathy who met the International Society of Thrombosis and Haemostasis (ISTH) diagnostic criteria for disseminated intravascular coagulopathy (DIC) had decreased survival; 71% of non-survivors had DIC compared to 0.6% of survivors [2]. Post-mortem examinations show severe endothelial injury with intracellular virus and widespread thrombotic microangiopathy in the pulmonary vasculature [3]. Hence, altered coagulation parameters in COVID-19 are a suspected indicator of thrombotic complications rather than bleeding risk.

One study reported improved 28-day mortality in severe COVID-19 patients with markedly elevated D-dimers who received low-molecular-weight heparin (LMWH) at 40–60 mg daily [4]. This has led to adoption of prophylactic and therapeutic anticoagulation guided by D-dimer levels. Post-mortem examinations show severe endothelial injury and widespread thrombotic microangiopathy in the pulmonary vasculature. Early reports describing the use of prophylactic anticoagulation demonstrated improved survival, leading to the adoption of prophylactic and therapeutic anticoagulation guided by D-dimer levels. The clinical usefulness of D-dimer values, trends, and more intensive anticoagulation remains an area of clinical interest.

**Background:** SARS-CoV-2 infection has noted derangements in coagulation markers along with significant thrombotic complications. Post-mortem examinations show severe endothelial injury and widespread thrombotic microangiopathy in the pulmonary vasculature. Early reports describing the use of prophylactic anticoagulation demonstrated improved survival, leading to the adoption of prophylactic and therapeutic anticoagulation guided by D-dimer levels. The clinical usefulness of D-dimer values, trends, and more intensive anticoagulation remains an area of clinical interest.

**Objectives:** Assess the outcomes and laboratory trends in COVID-19 patients stratified by intensity of anticoagulation at time of admission.

**Patients and methods:** Retrospectively review the differences in clinical outcomes and laboratory trends in patients hospitalized with COVID-19 in the Lifespan Health System.

**Results:** Between 27 February and 24 April 2020, 468 patients were hospitalized. Initial use of high-intensity thromboprophylaxis was associated with improved 30-day mortality (adjusted RR 0.26; 95% confidence interval [CI], 0.07–0.97; p = 0.045) without a significant increased rate of bleeding (p = 0.11).

In severe COVID-19, D-dimer significantly increased during hospitalization with standard thromboprophylaxis (p < 0.001) but remained stable or decreased with high-intensity prophylaxis or therapeutic anticoagulation.

**Conclusion:** Patients who received high-intensity prophylactic anticoagulation had a downtrend in D-dimer levels and improved 30-day mortality. This suggests a role in anticoagulation in mitigating adverse outcomes associated with COVID-19; however, further randomized, prospective studies are needed.
including deep venous thrombosis (DVT) and pulmonary embolism (PE) and cerebrovascular accident (CVA) at 30-days after diagnosis. Secondary endpoints were rates of bleeding while on anticoagulation and changes in D-dimer levels from admission throughout hospitalization. Categorical variables were compared with $\chi^2$ or Fisher's exact tests and continuous variables using Mann-Whitney test as appropriate. We examined the association between binary outcomes (30-day mortality, occurrence of thrombosis) and exposure in a multivariable generalized linear model (GLM, with Poisson distribution and robust standard error) adjusting for age, sex, indicators of COVID-19 severity, baseline comorbidities, and baseline anticoagulant use. Changes in the D-dimer levels were examined in a hierarchical GLM with a random intercept for each individual patient.

Severe COVID-19 pneumonia was associated with increased risk of VTE (9% vs 4%, $p = 0.026$), CVA (5% vs 1%, respectively, $p = 0.004$), and higher 30-day mortality (45% vs 5%, $p < 0.001$). Patient in the non-severe cohort developed VTE localized to the lower extremities. In the severe cohorts, the majority of VTE were localized to the lower extremities with 1 in the brachial vein, 1 in the axillary vein, and 1 in the internal jugular vein thrombus that was catheter-related. Of the lower extremity VTEs, 1 was in the bilateral peroneal veins and the remainder were proximally located. Patients were only evaluated for VTEs if there was clinical suspicion. There was no statistical difference in rate of PE (2% vs 1%, $p = 0.279$) or DVT (6% vs 2%, $p = 0.054$) in severe versus non-severe COVID-19. Furthermore, when compared to patients with non-severe COVID-19 pneumonia, those with severe COVID-19 had significantly increased risk of developing acute kidney injury (AKI) (68% vs 9%, $p < 0.001$) and AKI requiring the use of hemodialysis (16% vs 0%, $p < 0.001$). Patients with severe COVID-19 pneumonia were also more likely to receive high-intensity thromboprophylaxis or therapeutic anticoagulation than patients with non-severe COVID-19 pneumonia, without a significant difference in overall rates of bleeding (p = 0.11), including World Health Organization grade 3 ($p = 0.41$) or grade 4 bleeding rates ($p = 0.65$). A D-

![Fig. 1.](image-url)
dimer > 1000 ng/mL on admission was associated with a higher risk of VTE (23% vs 3%, \( p < 0.001 \)) and 30-day mortality (39% vs 12%, \( p < 0.001 \)).

In a multivariable model (Table 1 in Supplementary Appendix), 30-day mortality was significantly lower among all patients who received high-intensity thromboprophylaxis (adjusted relative risk [RR] versus standard-intensity, 0.26; 95% confidence interval [CI], 0.07–0.97, \( p = 0.045 \)) and a non-significant association was observed among patients with severe COVID-19 (adjusted RR = 0.32; 95% CI, 0.07–1.56, \( p = 0.15 \)). Of note, patients who received therapeutic anticoagulation had statistically higher 30-day mortality when compared to the standard and high-intensity prophylaxis cohorts (40% vs 15% vs 6%, respectively, \( p < 0.001 \)). Of note, patients who received therapeutic anticoagulation had statistically higher rates of acute respiratory distress syndrome (27% vs 16% vs 13%, respectively, \( p = 0.011 \)) and AKI (54% vs 33% vs 31%, respectively, \( p = 0.024 \)), suggesting that the higher 30-day mortality is likely due to the selection of a more critically ill population. Patients who received therapeutic anticoagulation had non-statistically higher rates of VTE when compared to the standard prophylaxis cohort (10% vs 5%, \( p = 0.19 \)); however, 80% of the VTEs in this cohort was found on admission, leading to therapeutic anticoagulation as the initial strategy. Additional patient characteristics and outcomes stratified by intensity of anticoagulation are reported in Table 1. In severe COVID-19, D-dimer significantly increased during hospitalization with standard thromboprophylaxis (\( p < 0.001 \)). However, D-dimer levels remained stable with high-intensity prophylaxis and decreased with therapeutic anticoagulation (Fig. 1).

It has been widely recognized that patients with COVID-19 have dramatically altered coagulation parameters and are prone to develop thrombotic complications in more severe cases with markedly elevated D-dimer levels associated with higher mortality [5]. Thus far, the adoption of prophylactic LMWH in the management of patients hospitalized with COVID-19 is based upon prospective data.

The question remains on whether standard VTE prophylaxis is adequate for VTE prevention. In our retrospective study, we found that patients who initially received high-intensity prophylaxis or therapeutic anticoagulation had improved 30-day mortality without increased rates of bleeding. Of note is that patients in our study with severe COVID-19 showed only a non-significant improvement in 30-day mortality with initial high-intensity prophylaxis. Further examination of the risks and benefits of high-intensity prophylaxis in COVID-19 is therefore warranted.

The early initiation of therapeutic anticoagulation with unfractonated heparin to prevent clinical deterioration in patients with severe forms of COVID-19 is based upon the observation that higher fibrinogen levels in COVID-19 patients can lead to heparin resistance thereby reducing the efficacy of standard thromboelobolic prophylaxis [6]. Higher levels of fibrinogen are also associated with increased risk of thrombosis [7]. As result, it has proposed that patients with COVID-19 may require more aggressive anticoagulation regimes, such as high-intensity prophylactic or therapeutic anticoagulation, to prevent clinical deterioration and multi-organ failure from thrombotic microangiopathy.

It has been recognized that elevations in D-dimer levels in COVID-19 patients is indicative of a hypercoagulable state and has been prognostic of in-hospital mortality [2]. In our study population, elevated D-dimer levels was associated with higher rates of VTE along with 30-day mortality. The hypercoagulable state has been thought to be attributed to dysfunction of endothelial cells through direct injury leading to excess thrombin generation leading to the thrombotic microangiopathy found on post-mortem examinations [3]. In addition, COVID-19 infection has been associated with an aggressive pro-inflammatory response which further contributes to hypercoagulability as described by Virchow’s triad. Prior publications have detailed the anti-inflammatory properties of heparin and heparin-related products through the binding of inflammatory cytokines, inhibition of neutrophil chemotaxis and leukocyte migration, and the sequestration of acute phase reactants and complement [8]. Other properties unrelated to direct anticoagulation effects that have been described include the interaction with the S1 spike protein of COVID-19, preventing viral adhesion, attachment, and cellular entry leading to direct endothelial injury, thrombin generation, and downstream thrombotic microangiopathy [9,10]. In our study, the increase in D-dimer levels during hospitalization in patients who received high-intensity prophylactic or therapeutic anticoagulation underscores both its potential efficacy in primary prevention of thrombosis and its anti-inflammatory effects in mitigating further thrombosis. This effect on D-dimer trends was not seen with standard prophylaxis in severe or non-severe COVID-19 which suggests that more intensive anticoagulation regimens are required for effective prevention of thrombosis in COVID-19.

Our study is limited by its single-institution, retrospective case-control design with a small sample sizes of patients initially treated with high-intensity thromboprophylaxis. Nonetheless, in hospitalized patients with mild or moderate forms of COVID-19, the use of high-

### Table 1

| Patient characteristics stratified by no prophylaxis, standard prophylaxis, high-intensity prophylaxis, or therapeutic anticoagulation. |
|---|
| Factor | None | Standard prophylaxis | High-intensity prophylaxis | Therapeutic anticoagulation | \( p \)-Value |
| N | 27 | 377 | 16 | 48 | 0.005 |
| Median age at presentation, years [IQR] | 70 [45–82] | 60 [49–73] | 61.5 [53–67.5] | 69 [61–79.5] | 0.005 |
| Male, n (%) | 15 (55.6%) | 210 (55.7%) | 7 (43.8%) | 25 (52.1%) | 0.79 |
| Charlson Comorbidity Index, median [IQR] | 4 [0–6] | 3 [1–5] | 3 [2–4.5] | 5 [3–7] | <0.001 |
| CAD, n (%) | 5 (18.5%) | 46 (12.2%) | 2 (12.5%) | 18 (37.5%) | <0.001 |
| Diabetes, n (%) | 4 (14.8%) | 131 (34.7%) | 7 (43.8%) | 26 (54.2%) | 0.004 |
| COPD, n (%) | 3 (11.1%) | 35 (9.3%) | 4 (25.0%) | 7 (14.6%) | 0.14 |
| Severe COVID-19 pneumonia, n (%) | 5 (18.5%) | 113 (30.0%) | 7 (43.8%) | 26 (54.2%) | 0.002 |
| ICU Admission, n (%) | 1 (3.7%) | 103 (27.3%) | 8 (50%) | 22 (45.8%) | <0.001 |
| ARDS, n (%) | 0 | 59 (15.6%) | 2 (12.5%) | 13 (27.1%) | 0.011 |
| AKI, n (%) | 2 (7.4%) | 123 (32.6%) | 5 (31.3%) | 26 (54.2%) | 0.024 |
| Disseminated intravascular coagulation, n (%) | 0 | 2 (0.5%) | 0 | 1 (2.1%) | 0.201 |
| VTE, n (%) | 0 | 18 (4.8%) | 1 (6.3%) | 5 (10.4%) | 0.19 |
| DVT, n (%) | 0 | 14 (3.7%) | 1 (6.3%) | 1 (2.1%) | 0.701 |
| Pulmonary embolism, n (%) | 0 | 4 (1.1%) | 0 (0%) | 4 (8.3%) | 0.021 |
| Cerebrovascular accidents, n (%) | 2 (7.4%) | 8 (2.1%) | 0 | 1 (2.1%) | 0.24 |
| WHO any grade bleeding events, n (%) | 0 | 10 (13%) | 0 | 7 (15%) | 0.88 |
| WHO grade 3 bleeding events, n (%) | 0 | 5 (6%) | 0 | 1 (2%) | 0.62 |
| WHO grade 4 bleeding events, n (%) | 0 | 3 (4%) | 0 | 2 (4%) | 1.0 |
| 30-day mortality, n (%) | 8 (29.6%) | 56 (14.9%) | 1 (6.3%) | 19 (39.6%) | <0.001 |
intensity prophylactic anticoagulation may be an acceptable strategy for more aggressive anticoagulation, while in severe forms of COVID-19 high-intensity prophylactic or even therapeutic anticoagulation in the absence of thrombosis may be acceptable regimens. Although ultimately the utility of high-intensity prophylactic anticoagulation requires confirmation in an adequately powered clinical study, our results, when coupled with the wide availability and clinical familiarity of VTE prophylaxis, warrants consideration of high-intensity prophylaxis in the current standard of care treatment of COVID-19 patients.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.thromres.2020.09.030.

Consent

This study was approved by the Institutional Review Board at Lifespan Health System.

CRediT authorship contribution statement

Andrew Hsu: Data curation, Investigation, Writing - original draft, Writing - review & editing, Validation. Yuchen Liu: Data curation, Investigation, Writing - original draft, Writing - review & editing, Validation. Adam S. Zayac: Data curation, Investigation, Writing - original draft, Writing - review & editing, Validation. Adam J. Olszewski: Formal analysis, Writing - original draft, Writing - review & editing, Validation. John L. Reagan: Formal analysis, Writing - original draft, Writing - review & editing, Validation.

Declaration of competing interest

The authors declare no conflicts of interest.

References

[1] C. Huang, Y. Wang, X. Li, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506 Feb 15.
[2] N. Tang, D. Li, X. Xang, et al., Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemost. 18 (4) (2020) 844–847, Apr.
[3] M. Ackermann, S.E. Verleden, M. Kuechnel, et al., Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19, N. Engl. J. Med. (2020), https://doi.org/10.1056/NEJMoct203432 May 21. (Online ahead of print).
[4] N. Tang, H. Bai, X. Chen, et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost. 18 (2020) 1094–1099.
[5] J.P. Metlay, G.W. Waterer, A.C. Long, et al., Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America, Am. J. Respir. Crit. Care Med. 200 (7) (2019) e45–e67.
[6] J.N. Harr, E.E. Moore, T.L. Chin, et al., Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis, Shock 41 (2014) 33–39.
[7] J. Klovaite, R.G. Nordsetgaard, A. Tybjaerg-Hansen, et al., Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis, Am. J. Respir. Crit. Care Med. 187 (2013) 286–293.
[8] J.P. Li, I. Vlodavsky, Heparin, heparan sulfate and heparanase in inflammatory reactions, Thromb. Haemost. 102 (5) (2009) 823–828.
[9] C. Mycroft-West, D. Su, S. Elli, et al., The 2019 coronavirus (SARS-CoV-2) surface protein (Spieke) S1 Receptor Binding Domain undergoes conformational change upon heparin binding, bioRxiv (2020), https://doi.org/10.1101/2020.02.29.971093.
[10] J. Ma, J. Bai, Protective effects of heparin on endothelial cells in sepsis, Int. J. Clin. Exp. Med. 8 (6) (2015) 5547–5552.

Andrew Hsu⁎, Yuchen Liu⁎, Adam S. Zayac⁎, Adam J. Olszewski⁎, John L. Reagan⁎

⁎Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI, United States of America

⁎Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, United States of America

E-mail address: Andrew_hsu1@brown.edu (A. Hsu).

⁎ Corresponding author at: 593 Eddy Street, Providence, RI 02903, United States of America.